Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
Authors
Keywords
-
Journal
mAbs
Volume 10, Issue 6, Pages 827-842
Publisher
Informa UK Limited
Online
2018-08-31
DOI
10.1080/19420862.2018.1484977
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
- (2018) G.S. Fernandes et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
- (2018) Myrna Candelaria et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer
- (2017) Hope S. Rugo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
- (2017) Justin Stebbing et al. LANCET ONCOLOGY
- Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products
- (2017) Brian Hassett et al. mAbs
- Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
- (2017) Won Seog Kim et al. Lancet Haematology
- Statistical Primer on Biosimilar Clinical Development
- (2016) Leah Isakov et al. AMERICAN JOURNAL OF THERAPEUTICS
- Clinical trials of biosimilars should become more similar
- (2016) Jonathan Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0224 Comparison of Efficacy and Safety of Rituximab Biosimilar, BCD-020, and Innovator Rituximab in Patients with Active Rheumatoid Arthritis Refractory To TNFA Inhibitors
- (2016) A. Eremeeva et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
- (2016) Ira Jacobs et al. BIODRUGS
- Gota et al. on their article “the pharmacokinetics of Reditux™, a biosimilar of rituximab”
- (2016) Mira Tout et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A clinician’s guide to biosimilars in oncology
- (2016) Hope S. Rugo et al. CANCER TREATMENT REVIEWS
- Biosimilars: Extrapolation for oncology
- (2016) Giuseppe Curigliano et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
- (2016) Silvio Danese et al. Journal of Crohns & Colitis
- Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America
- (2016) Claudia de la Cruz et al. JOURNAL OF DERMATOLOGY
- Postmarket policy considerations for biosimilar oncology drugs
- (2016) Matthew J Renwick et al. LANCET ONCOLOGY
- Biosimilars in rheumatology: understanding the rigor of their development
- (2016) Niti Goel et al. RHEUMATOLOGY
- Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
- (2016) Eduardo Mysler et al. RHEUMATOLOGY INTERNATIONAL
- The Regulation of Biosimilars in Latin America
- (2016) Ricardo Garcia et al. Current Rheumatology Reports
- Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
- (2016) Filipe C. Araújo et al. Current Rheumatology Reports
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
- (2015) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease—Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases
- (2015) Valderílio Feijó Azevedo et al. AUTOIMMUNITY REVIEWS
- Access to an optimal treatment. Current situation
- (2015) Manuel F. Ugarte-Gil et al. CLINICAL RHEUMATOLOGY
- Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view
- (2015) Carlos Pineda et al. CLINICAL RHEUMATOLOGY
- Biosimilar monoclonal antibodies: the scientific basis for extrapolation
- (2015) Huub Schellekens et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Biosimilar monoclonal antibodies in lymphoma: a critical appraisal
- (2015) Catherine Rioufol et al. Expert Review of Anticancer Therapy
- A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
- (2015) Rajendrakumar H. Jani et al. International Journal of Rheumatic Diseases
- Progress and remaining challenges for cancer control in Latin America and the Caribbean
- (2015) Kathrin Strasser-Weippl et al. LANCET ONCOLOGY
- Biosimilars in rheumatology: current perspectives and lessons learnt
- (2015) Thomas Dörner et al. Nature Reviews Rheumatology
- Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe
- (2015) Fanni Rencz WORLD JOURNAL OF GASTROENTEROLOGY
- Development of biosimilars in an era of oncologic drug shortages
- (2015) Edward Li et al. Drug Design Development and Therapy
- Optimizing the use of biological therapy in patients with inflammatory bowel disease
- (2015) A. C. Moss Gastroenterology Report
- The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
- (2015) Jaana T. Joensuu et al. PLoS One
- OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses
- (2014) J. Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- Biosimilars: the science of extrapolation
- (2014) M. Weise et al. BLOOD
- Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales
- (2014) C Chamberlain et al. BRITISH JOURNAL OF CANCER
- The global challenges and opportunities in the practice of rheumatology: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases
- (2014) Mustafa Al Maini et al. CLINICAL RHEUMATOLOGY
- Traceability of biologicals: present challenges in pharmacovigilance
- (2014) Niels S Vermeer et al. Expert Opinion On Drug Safety
- Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
- (2014) Gilberto Castañeda-Hernández et al. JOINT BONE SPINE
- Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
- (2014) Kirit M Ardeshna et al. LANCET ONCOLOGY
- Physicochemical characterization of Remsima®
- (2014) Soon Kwan Jung et al. mAbs
- Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
- (2014) Morton Scheinberg et al. ARTHRITIS RESEARCH & THERAPY
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Patient’s access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal
- (2013) Pedro A Laires et al. BMC MUSCULOSKELETAL DISORDERS
- ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
- (2013) Silvio Danese et al. Journal of Crohns & Colitis
- Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis—the Health Outcomes Patient Environment (HOPE) study
- (2013) Kyriakos Souliotis et al. RHEUMATOLOGY INTERNATIONAL
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
- Biosimilars in rheumatology: a view from Latin America
- (2012) Eduardo Mysler et al. CLINICAL RHEUMATOLOGY
- The advent of biosimilar therapies in rheumatology—“O Brave New World”
- (2012) Morton A. Scheinberg et al. Nature Reviews Rheumatology
- Less Than Ideal: How Oncologists Practice With Limited Drug Access
- (2012) Kelvin K. Chan et al. Journal of Oncology Practice
- Judicialisation of the right to health in Brazil
- (2009) João Biehl et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started